国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2010年
11期
1338-1340
,共3页
低分子肝素钙%降纤酶%短暂性脑缺血发作
低分子肝素鈣%降纖酶%短暫性腦缺血髮作
저분자간소개%강섬매%단잠성뇌결혈발작
Low molecular calcium%Defibrase%Transient ischemic attack
目的 探讨低分子肝素钙联合降纤酶治疗短暂性脑缺血发作(TIA)的临床效果.方法 将2008年1月-2009年6月间在我院住院治疗的TIA患者70例随机分为观察组和对照组,对照组给予双嘧达莫联合阿司匹林治疗,观察组给予低分子肝素钙联合降纤酶治疗,观察两组疗效.结果 TIA终止小于1 d者观察组26例,对照组16例,两组比较差异有显著性(P<0.05).脑梗塞患者观察组1例.对照组8例,两组比较差异有显著性(P<0.05).观察组总有效率为97.14%,对照组为77.14%,两组比较差异有显著性(P<0.05).两组患者均未见明显的药物不良反应.结论 低分子肝素钙联合降纤酶治疗TIA效果更好,值得应用.
目的 探討低分子肝素鈣聯閤降纖酶治療短暫性腦缺血髮作(TIA)的臨床效果.方法 將2008年1月-2009年6月間在我院住院治療的TIA患者70例隨機分為觀察組和對照組,對照組給予雙嘧達莫聯閤阿司匹林治療,觀察組給予低分子肝素鈣聯閤降纖酶治療,觀察兩組療效.結果 TIA終止小于1 d者觀察組26例,對照組16例,兩組比較差異有顯著性(P<0.05).腦梗塞患者觀察組1例.對照組8例,兩組比較差異有顯著性(P<0.05).觀察組總有效率為97.14%,對照組為77.14%,兩組比較差異有顯著性(P<0.05).兩組患者均未見明顯的藥物不良反應.結論 低分子肝素鈣聯閤降纖酶治療TIA效果更好,值得應用.
목적 탐토저분자간소개연합강섬매치료단잠성뇌결혈발작(TIA)적림상효과.방법 장2008년1월-2009년6월간재아원주원치료적TIA환자70례수궤분위관찰조화대조조,대조조급여쌍밀체막연합아사필림치료,관찰조급여저분자간소개연합강섬매치료,관찰량조료효.결과 TIA종지소우1 d자관찰조26례,대조조16례,량조비교차이유현저성(P<0.05).뇌경새환자관찰조1례.대조조8례,량조비교차이유현저성(P<0.05).관찰조총유효솔위97.14%,대조조위77.14%,량조비교차이유현저성(P<0.05).량조환자균미견명현적약물불량반응.결론 저분자간소개연합강섬매치료TIA효과경호,치득응용.
Objective To investigate the efficacy of low molecular calcium combined with defibrase for transient ischemic attack (TIA). Method 70 patients who were hospitalized from January 2008 to June 2009 were randomly assigned to receive low molecular calcium combined with defibrase (study group), or dipyridamole plus acenterine (control group). The efficacy of the two therapies was compared. Results There was a significant difference between the study group and the control group in the number of patients who had TIA cessation within one day or who developed cerebral infarction (26 vs. 16 and 1 vs. 8, P<0.05 for both comparisons). The total effective rate differed significantly between the two groups (97. 14% in the study group vs. 76.14% in the control group, P<0.05). No marked adverse reactions were found in all the patients. Conclusions Low molecular calcium combined with defibrase for transient ischemic attack has a better efficacy and is worth popularizing.